Tennessee is currently home to 1927 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Nashville, Memphis, Knoxville and Chattanooga. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study
NCT05405374
Recruiting
The objective of this clinical study is to compare OSTEOAMP SELECT Fibers to Infuse Bone Graft, in terms of effectiveness and safety, when used as a bone graft substitute in in skeletally mature patients qualified for 2-lumbar interbody fusion (LIF) by means of an intra-patient control model.
Gender:
All
Ages:
Between 21 years and 80 years
Trial Updated:
08/25/2023
Locations: Tennessee Orthopaedic Alliance, Nashville, Tennessee
Conditions: Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
Register for Updates
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
NCT04056247
Recruiting
This study will develop an algorithm of identifying patients with stage IV NSCLC and Melanoma who could benefit from cancer treatment they receive.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/25/2023
Locations: West Clinic, Germantown, Tennessee
Conditions: Stage IV Non-small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Stage III Malignant Melanoma, Stage IV Malignant Melanoma
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: GSK Investigational Site, Nashville, Tennessee
Conditions: Neoplasms
Register for Updates
Screening Protocol for Tumor Antigen Expression Profiling and HLA Typing for Eligibility Determination
NCT02636855
Recruiting
This screening study is intended for men and women ≥ 18 to ≤ 75 years of age who have advanced solid or hematologic malignancy. The study will assess a subject's human leukocyte antigen (HLA) subtype and tumor antigen expression profile. Based on the results, it will be determined if a subject is eligible to be considered for Adaptimmune sponsored clinical trials testing the safety and efficacy of genetically changed T cells targeting specific tumor antigens. No treatment intervention will occur... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/18/2023
Locations: Tennessee Oncology- Sarah Cannon Research Institute, Nashville, Tennessee
Conditions: Solid and Hematological Malignancies
Register for Updates
Total Shoulder Arthroplasty Multi-Center Registry
NCT03511586
Recruiting
The objective of the study is a multi-center prospective registry to collect clinical outcomes of anatomic and reverse total shoulder arthroplasty.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
07/27/2023
Locations: Not set, Germantown, Tennessee
Conditions: Shoulder Arthroplasty
Register for Updates
Collection of Sputum and Labeling for Lung Cancer
NCT03457415
Recruiting
The primary objective of this study is to compare Assay results to diagnoses determined by currently accepted standards for lung cancer detection. This will be accomplished by analysis of sputum samples from three cohorts including healthy Participants, high risk Participants, and cancer patient Participants using the Assay as developed in accordance with findings of bioAffinity protocol BA-001 to confirm assay results. Adjustments will be made as necessary to finalize Assay design for clinical... Read More
Gender:
All
Ages:
21 years and above
Trial Updated:
07/25/2023
Locations: Cookeville Regional Medical Center - Cancer Center, Cookeville, Tennessee
Conditions: Lung Cancer
Register for Updates
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT05708950
Recruiting
The goal of this clinical trial is to test the safety and efficacy of KVA12123 alone or combined with pembrolizumab in patients with advanced solid tumors. The main questions this study aims to answer are: What is the safety of KVA12123 when administered alone and in combination with pembrolizumab to advanced cancer patients? What is an appropriate dose of KVA12123 to administer alone and in combination with pembrolizumab to advanced cancer patients in future clinical trials? Participants in t... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
07/11/2023
Locations: Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee
Conditions: Cancer, Solid Tumor, Melanoma, Carcinoma, Sarcoma, Lung Cancer, Prostate Cancer, Breast Cancer, Colo-rectal Cancer, Uterine Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Thyroid Cancer, Ovarian Cancer, Kidney Cancer, Head and Neck Cancer
Register for Updates
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
NCT05951816
Recruiting
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic amyloidosis, notably with cardiac involvement.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/10/2023
Locations: University of Tennessee Graduate School of Medicine, Knoxville, Tennessee
Conditions: Systemic Amyloidosis
Register for Updates
Evaluate the Continued Safety and Performance of the Foot and Ankle Products
NCT04715139
Recruiting
The objective of the registry is to evaluate the continued safety and performance of the Arthrex foot and ankle products including the ProStop implant for hyperpronated foot, Bio-Compression Screw for reconstruction surgeries of the foot, TRIM-IT Drill Pin, TRIM-IT Spin Pin for fixation of fractures and fusion (bunionectomy osteotomies) of the foot/ankle, Headless Compression Screws and Compression FT Screws for fixation of small bone fragments of the foot/ankle and DynaNite® Nitinol Staple to b... Read More
Gender:
All
Ages:
2 years and above
Trial Updated:
06/26/2023
Locations: TOA Research Foundation, Nashville, Tennessee
Conditions: Hyperpronated Foot, Reconstruction Surgeries of the Foot, Fixation of Fractures and Fusion (Bunionectomy Osteotomies) of the Foot/Ankle, Fixation of Small Bone Fragments of the Foot/Ankle, Lisfranc Arthrodesis, Mono or Bi-cortical Osteotomies in the Forefoot, First Metatarsophalangeal Arthrodesis, Akin Osteotomy, Midfoot and Hindfoot Arthrodeses or Osteotomies, Fixation of Osteotomies for Hallux Valgus Treatment (Scarf and Chevron), Arthrodesis of the Metatarsocuneiform Joint to Reposition and Stabilize Metatarsus Primus Varus, Osteotomy Fixation of Hallux Valgus Repair (Such as Scarf and Chevron Etc.)
Register for Updates
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
NCT04061421
Recruiting
ABNL-MARRO (A Basket study of Novel therapy for untreated MDS/MPN and Relapsed/Refractory Overlap Syndromes) is an international European-American cooperation providing the framework for collaborative studies to advance treatment of myelodysplastic/myeloproliferative neoplasms (MDS/MPN) and explore clinical-pathologic markers of disease severity, prognosis and treatment response. ABNL MARRO 001 (AM-001) is an Open label, phase 1/2 study within the framework of the ABNL-MARRO that will test nove... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/22/2023
Locations: Vanderbilt-Ingram Cancer Center, Nashville, Tennessee
Conditions: MDS/MPN
Register for Updates
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
NCT05268666
Recruiting
The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2023
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Locally Advanced Solid Tumor, Metastatic Solid Tumor
Register for Updates
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
NCT03901807
Recruiting
Prospective, multicenter, randomized, open-label study of standard of care plus the PMX cartridge versus standard of care alone in patients with endotoxemic septic shock
Gender:
All
Ages:
18 years and above
Trial Updated:
06/08/2023
Locations: CHI Memorial, Chattanooga, Tennessee
Conditions: Septic Shock, Endotoxemia
Register for Updates